Treatment of Sual-e-Yabis (Dry Cough) with Unani medicine Habb-e-Luab-e-Behidana

Phase 3

Not yet recruiting

• Conditions: Cough,

• Registration Number: CTRI/2021/12/038808
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a multicentric open trial in patients with **Sual-e-Yabis (Dry Cough)**.After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically at every week. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be two weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

Composition of *Habb-e-Luab-Behidana*     

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical Name**

**Quantity**

|1.

Maghz -e –Behidana

*Cydonia oblonga* Mill.

2 g

|2.

Maghz -e -Tukhm e Kadu

*Cucurbita moschata* Duchesne.

2 g

|3.

Maghz –e- Tukhm- e- Khiyarain

*Cucumis sativus* Linn.

*Cucumis melo* Linn.

2 g

|4.

Zafran

*Crocus sativus* Linn.

1 g

|5.

Samagh -e –Arabi

*Acacia arabica* wild*.*

3 g

|6.

Nishasta

Starch

3 g

|7.

Kateera

*Cochlospermum religiosum (Linn.)* Alston.

3 g

|8.

Maghz- e -Badam shireen

*Prunus amygdalus* Batsch.

4 g

|9.

Rubbus-soos

*Glycyrrhiza glabra* Linn.

4 g

|10.

Maweez Munaqqa

*Vitis vinifera* Linn.

4 g

|11.

Tukhm-e -Khashkhash safaid

*Papaver somniferum* Linn.

4 g

|12.

Nabat safaid

Sugar

7 g

|13.

Luab -e –Behidana

*Cydonia oblonga* Mill.

Q.S.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-23

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

• Patients of either sex in the age group of 18-60 years.
• Sual-e-Yabis (Dry Cough) of < 3 weeks duration.

Exclusion Criteria

• Acute Upper Respiratory Tract Infections (URI or URTI) 2.
• Acute Lower Respiratory Tract Infections (LRI or LRTI) including pneumonia, lung abscess, and acute bronchitis.
• Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema.
• Bronchiectasis, pulmonary tuberculosis, pulmonary oedema, interstitial pulmonary fibrosis 5.
• Tumours of larynx, bronchi, and lungs 6.
• Diabetes Mellitus, Hypertension 8.
• Known cases of severe hepatic, renal or cardiac ailments 9.
• Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in sign and symptoms of Sual-e-Yabis (Dry Cough)	2 weeks

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	Investigations will be done at baseline and end of treatment

Trial Locations

Locations (2)

Clinical Research Unit (CRU), Meerut; 🇮🇳 Meerut, UTTAR PRADESH, India

Regional Research Centre, Allahabad; 🇮🇳 Allahabad, UTTAR PRADESH, India

Clinical Research Unit (CRU), Meerut

🇮🇳Meerut, UTTAR PRADESH, India

Dr Mohd Naseem

Principal investigator

8451934661

naseemrrium786@gmail.com